Introduction {#s1}
============

Multiple sclerosis (MS) is a complex neurological disease with a strong genetic predisposition, as demonstrated by genetic--epidemiological studies \[[@pgen-0030150-b001]--[@pgen-0030150-b003]\]. However, the mapping of putative susceptibility genes has proven difficult. The imputation of many non--major histocompatibility complex (MHC) genes by analogies with experimental models and the drop in concordance between monozygotic and dizygotic twins, has not been validated by genome scans. In genome-wide studies with enough power to detect relatively small effects, the MHC has consistently been the only locus linked to MS \[[@pgen-0030150-b004]\]. This indicates that the MHC is the key susceptibility locus in MS and other susceptibility genes contribute relatively little to overall risk \[[@pgen-0030150-b031]\].

Accordingly, polymorphisms at the major histocompatibility locus (MHC) have undergone renewed study. Genes in the HLA class I region were originally shown to be associated with MS \[[@pgen-0030150-b005],[@pgen-0030150-b006]\] but stronger associations were subsequently observed in the class II region of the MHC \[[@pgen-0030150-b007]\]. This class II association has been fine mapped to the extended haplotype *HLA-DQA1\*0102-DQB1\*0602-DRB1\*1501-DRB5\*0101* \[[@pgen-0030150-b008],[@pgen-0030150-b009]\].

The human leukocyte antigen (HLA) association in a large Canadian MS population was recently revisited \[[@pgen-0030150-b010]\] and the situation was found to be much more complex than originally conceived. The study of interactions was only productive when a large sample was analysed (*n* = 4,347 individuals). The *HLA-DRB1\*17* allele has long been known to be associated with susceptibility in other groups, in particular the Sardinian and the Swedish MS populations \[[@pgen-0030150-b011],[@pgen-0030150-b012]\] and this was confirmed in the Canadian population.

There were clear indications of resistance alleles, in particular, *HLA-DRB1\*14,* and the same approach was recently repeated in a study of American and European families \[[@pgen-0030150-b013]\] with similar results. Additionally, *HLA-DRB1\*08* and *DRB1\*01* showed effects on MS risk in the presence of *HLA-DRB1\*15* \[[@pgen-0030150-b010]\]. We present here an investigation of an expanded series of Canadian MS families aimed at elucidating the inheritance pattern of MS susceptibility and resistance alleles.

Results {#s2}
=======

A total of 7,093 individuals from 1,432 families have been typed as part of the Canadian Collaborative Project on the Genetic Susceptibility to MS (CCPGSMS). This includes 2,454 individuals with definite MS and 4,639 of their unaffected first-degree relatives.

Transmission Disequilibrium Test Analysis of All *HLA-DRB1* Alleles {#s2a}
-------------------------------------------------------------------

In the total sample, *HLA-DRB1\*15* was transmitted 953 times and not transmitted 392 times; χ^2^ = 233.99 (*p* = 8.0 × 10^−53^). To avoid confounding results due to the over transmission of *HLA-DRB1\*15,* transmissions from only non-*HLA-DRB1\*15*-bearing parents were examined. *HLA-DRB1\*17* was transmitted (TR) 306 times and not transmitted (NT) 222 times; odds ratio (OR) = 1.4, χ^2^ = 13.36 (*p* = 0.00026)*. HLA-DRB1\*14* continues to be protective; TR = 23, NT = 66, OR = 0.35, χ^2^ = 20.78 (*p* = 5.2× 10^−6^) and *HLA-DRB1\*11* was also found to be significantly under transmitted (TR = 157, NT = 213) even after applying a Bonferroni correction for multiple testing (*p* = 0.0036, *p*~c~ = 0.047). *HLA-DRB1\*08* (*p* = 0.0058) and *HLA-DRB1\*12* (*p* = 0.041) were over and under transmitted, respectively, but would not be significant after applying a Bonferroni correction.

Transmission of *HLA-DRB1* alleles to unaffected offspring was also analysed. In the total sample, *HLA-DRB1\*15* was transmitted 518 times and not transmitted 616 times; χ^2^ = 8.47 (*p* = 0.0036, *p*~c~ = 0.047). Transmissions of *HLA-DRB1\*14* and *HLA-DRB1\*11* from non-*HLA-DRB1\*15*-bearing parents were TR = 42, NT = 42 (*p* = 1) and TR = 142, NT = 161 (*p* = 0.28), respectively.

Mode of Inheritance of *HLA-DRB1\*15* {#s2b}
-------------------------------------

The mode of inheritance of *HLA-DRB1\*15* was assessed by examining the segregation of the allele in various mating types ([Table 1](#pgen-0030150-t001){ref-type="table"}) where the genotypes of both parents were available. The genotype *HLA-DRB1\*15/X* had a 3.1-fold increased risk of MS over *HLA-DRB1\*X/X* (where "X" refers to all alleles other than *HLA-DRB1\*15*). An individual homozygous for *HLA-DRB1\*15* had a 1.8-fold increased risk over a heterozygous *HLA-DRB1\*15* individual; χ^2^ = 20.24 (*p* = 6.8 × 10^−6^).

###### 

The Inheritance of HLA-DRB1\*15

![](pgen.0030150.t001)

Mode of Inheritance of *HLA-DRB1\*17* {#s2c}
-------------------------------------

The mode of inheritance for the *HLA-DRB1\*17* susceptibility allele was assessed in a similar manner. In the total sample, *HLA-DRB1\*17/17 or HLA-DRB1\*17/X* showed no increased frequency in the genotypes of the affected offspring (unpublished data). However, controlling for the effects of *HLA-DRB1\*15* by assessing only those parents lacking *HLA-DRB1\*15* (*n* = 179 nuclear families), *HLA-DRB1\*17* heterozygotes increased MS risk by 1.6-fold over *HLA-DRB1\*X/X* individuals (where "X" is neither *HLA-DRB1\*15* nor *DRB1\*17*) ([Table 2](#pgen-0030150-t002){ref-type="table"}). Additionally, *HLA-DRB1\*17* homozygosity further increased risk by 2.2-fold compared to a *HLA-DRB1\*17* heterozygote.

###### 

The Inheritance of *HLA-DRB1\*17* in the Absence of *HLA-DRB1\*15*

![](pgen.0030150.t002)

To test the relative and interactive effects of *HLA-DRB1\*17* and *DRB1\*15,* the offspring genotypes of the mating type *HLA-DRB1\*15/17* by *HLA-DRB1\*X/X* (where "X" is neither *HLA-DRB1\*15* nor *DRB1\*17*) were examined. If the two alleles are codominant in their mode of inheritance, there should be an equal proportion of *HLA DRB1\*17/X* and *HLA-DRB1\*15/X* offspring. In this mating type, there were 77 *HLA-DRB1\*15/X* offspring compared to 26 *HLA-DRB1\*17/X* offspring; χ^2^ = 25.25 (*p* = 5.0 × 10^−7^, p~c~=1.4x10^−5^). A confirmation of this can be given by the mating *HLA-DRB1\*15/X* by *HLA-DRB1\*17/X* (where "X" is neither *HLA-DRB1\*15* nor *DRB1\*17*). If *HLA-DRB1\*15* were dominant to *HLA-DRB1\*17*, the numbers of *HLA-DRB1\*15/17* offspring and *HLA-DRB1\*15/X* offspring should be equal. In this mating type, there were 74 *HLA-DRB1\*15/17* and 70 *HLA-DRB1\*15/X*; χ^2^ = 0.11 (*p* = 0.74).

Mode of Inheritance of *HLA-DRB1\*14* {#s2d}
-------------------------------------

The inheritance of the resistance allele, *HLA-DRB1\*14* was also examined. As with *HLA-DRB1\*17*, the inheritance of *HLA-DRB1\*14* was analysed with and without *HLA-DRB1\*15*-bearing parents. In the presence of *HLA-DRB1\*15* and *DRB1\*17,* the transmission of *HLA-DRB1\*14* was, expectedly, significantly under transmitted, OR = 0.31; χ^2^ = 29.8, (*p* = 4.8 × 10^−8^, *p*~c~ = 6.2 × 10^−7^). When the over transmission of *HLA-DRB1\*15* and *DRB1\*17* was controlled for, the OR of *HLA-DRB1\*14* was still significantly different from 1.0 ([Table 3](#pgen-0030150-t003){ref-type="table"}); OR = 0.27; (*p* = 0.0096, *p*~c~ = 0.27). There were no *HLA-DRB1\*14* homozygous parents, unaffected siblings, or MS cases observed in the entire sample.

###### 

The Inheritance of *HLA-DRB1\*14* in the Absence of *HLA-DRB1\*15* and *DRB1\*17*

![](pgen.0030150.t003)

To further assess the relative effects of *HLA DRB1\*14* and *DRB1\*15,* the offspring genotypes from *HLA-DRB1\*15/X* by *HLA-DRB1\*14/X* matings were examined (where "X" is neither *HLA-DRB1\*15* nor *DRB1\*14*). Possible offspring genotypes are *HLA-DRB1\*15/14*, *DRB1\*15/X*, *DRB1\*14/X,* and *DRB1\*X/X*. If *HLA-DRB1\*15* acts dominantly, numbers of *HLA-DRB1\*15/14* offspring should equal numbers of *HLA-DRB1\*15/X* offspring. Alternatively, if *HLA-DRB1\*14* acts dominantly over *HLA-DRB1\*15,* the numbers of *HLA-DRB1\*15/14* offspring should be less than *HLA-DRB1\*15/X* offspring. A total of 24 *HLA-DRB1\*15/X* offspring and seven *HLA-DRB1\*15/14* offspring were observed (*p* = 0.0017, *p*~c~ = 0.048). The OR of *HLA-DRB1\*15/14* over *HLA-DRB1\*X/X* (OR = 0.5) was not significantly different from expected, χ^2^ = 1.6, (*p* = 0.21). However, when the frequency of *HLA-DRB1\*15/14* was compared between affected (*n* = 10/2182) and unaffected (*n* = 30/2126) siblings, the OR = 0.30, χ^2^ = 10.63 (*p* = 0.0010, *p*~c~ = 0.028). Only one affected and one unaffected individual per family were included and the individuals were chosen randomly.

Mode of Inheritance of *HLA-DRB1\*11* {#s2e}
-------------------------------------

*HLA-DRB1\*11* was demonstrated to be a resistance allele in this cohort. To further evaluate the mode of inheritance of this resistance allele we repeated the previous inheritance analyses with *HLA-DRB1\*11* ([Table 4](#pgen-0030150-t004){ref-type="table"}). In *HLA-DRB1\*15-*negative families*,* there were 69 *HLA-DRB1\*11/X* offspring and 107 *HLA-DRB1\*X/X* children (where "X" is neither *HLA-DRB1\*15* nor *DRB1\*11*); OR = 0.64 (*p* = 0.0042, *p*~c~ = 0.12). *HLA-DRB1\*11/11* showed increased protection (OR = 0.44); however, this was not statistically significant. When the frequency of *HLA-DRB1\*11/11* was compared between affected (*n* = 4/2,182) and unaffected (*n* = 13/2,126) siblings, the OR = 0.38, χ^2^ = 5.02 (*p* = 0.025, *p*~c~ = 0.7).

###### 

The Mode of Inheritance of *HLA-DRB1\*11* in the Absence of *HLA-DRB1\*15*
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To examine the relative effects of *HLA-DRB1\*11* and *DRB1\*15,* matings of *HLA-DRB1\*11/X* by *HLA-DRB1\*15/X* and *HLA-DRB1\*11/X* and *HLA-DRB1\*15/15* (where "X" is neither *HLA-DRB1\*15* nor *DRB1\*11*) were assessed*.* There were 57 *HLA-DRB1\*11/15* and 98 *HLA-DRB1\*15/X* observed genotypes in the offspring. The number of *HLA-DRB1\*11/15* children was significantly decreased from the number of *HLA-DRB1\*15/X* offspring; OR = 0.58, χ^2^ = 10.85 (*p* = 0.00099, *p*~c~ = 0.028).

Mode of Inheritance of *HLA-DRB1\*08* {#s2f}
-------------------------------------

To assess the inheritance pattern of *HLA-DRB1\*08,* we counted offspring in *HLA-DRB1\*08/X* by *HLA-DRB1\*X/X* matings and *HLA-DRB1\*08/X* by *HLA-DRB1\*08/X* matings (where "X" is not *HLA-DRB1\*08*; there were no *HLA-DRB1\*08/08* parents or affected children). There were 92 *HLA-DRB1\*08/X* offspring and 83 *HLA-DRB1\*X/X* offspring; OR = 1.11 (*p* = 0.50). When *HLA-DRB1\*15* was removed from the sample in the above mating types, there were 36 *HLA-DRB1\*08/X* offspring and 21 *HLA-DRB1\*X/X* children; OR = 1.7, χ^2^ = 3.95 (*p* = 0.047; *p*~c~ = 0.99).

To examine the relative effects of *HLA-DRB1\*08* and *DRB1\*15,* matings of *HLA-DRB1\*08/X* by *HLA-DRB1\*15/X* and *HLA-DRB1\*08/X* and *HLA-DRB1\*15/15* (where "X" is neither *HLA-DRB1\*15* nor *DRB1\*08*) were assessed*.* There were 40 *HLA-DRB1\*08/15,* five *HLA-DRB1\*08/X,* 23 *HLA-DRB1\*15/X,* and nine *HLA-DRB1\*X/X* observed genotypes in the offspring. The number of *HLA-DRB1\*08/15* children was significantly increased from the number of *HLA-DRB1\*15/X* offspring; OR = 1.74 (*p* = 0.021; *p*~c~ = 0.44).

Mode of Inheritance of *HLA-DRB1\*10* {#s2g}
-------------------------------------

*HLA-DRB1\*10* is a rare allele in this sample (allele frequency = 0.6%) and numbers and mating types were few. However, in a previous investigation, it was found that *HLA-DRB1\*10* may have acted to modulate risk \[[@pgen-0030150-b010]\]. In this new dataset, the number of *HLA-DRB1\*15/10* to *HLA-DRB1\*15/X* offspring genotypes were compared in *HLA-DRB1\*10/X* by *HLA-DRB1\*15/X* matings (where "X" is neither *HLA-DRB1\*15* nor *DRB1\*10*); the numbers were one and ten, respectively, OR = 0.09 (*p* = 0.0059, *p*~c~ = 0.09).

In the absence of *HLA-DRB1\*15* (*HLA-DRB1\*10/X* by *HLA-DRB1\*X/X* matings, where "X" is not *HLA-DRB1\*10* or *DRB1\*15*), an opposite trend was observed with 12 *HLA-DRB1\*10/X* offspring to seven *HLA-DRB1\*X/X* offspring found; OR = 1.7 (*p* = 0.18).

To further investigate this contrary finding, we repeated the analysis of our previous investigation \[[@pgen-0030150-b010]\] using the newly ascertained families (*n* = 559) as a replication dataset ([Table 5](#pgen-0030150-t005){ref-type="table"}).

###### 

Transmission of *HLA-DRB1\*10* from non*-HLA-DRB1\*15-*Bearing Parents to Offspring Stratified by the Presence or Absence of *HLA-DRB1\*15*

![](pgen.0030150.t005)

In the new sample, the trend was in the same direction as the original finding in the Dyment et al. investigation \[[@pgen-0030150-b010]\]. When the results were combined, there was a significant difference in transmission of *HLA-DRB1\*10* from non*-HLA-DRB1\*15* parents based on the presence or absence of *HLA-DRB1\*15* in the offspring.

Mode of Inheritance of *HLA-DRB1\*01* {#s2h}
-------------------------------------

In our previous investigation \[[@pgen-0030150-b010]\], we saw differences in the transmission of *HLA-DRB1\*01* based on the presence or absence of *HLA-DRB1\*15*. While *HLA-DRB1\*01* is not protective in the total transmission disequilibrium test (TDT) from non-*HLA-DRB1\*15*-bearing parents (TR = 185, NT = 195, *p* = 0.61), further evaluation is warranted based on previous observations.

To examine the relative effects of *HLA-DRB1\*01* and *DRB1\*15,* matings of *HLA-DRB1\*01/X* by *HLA-DRB1\*15/X* and *HLA-DRB1\*01/X* and *HLA-DRB1\*15/15* (where "X" is neither *HLA-DRB1\*15* nor *DRB1\*01*) were assessed*.* There were 50 *HLA-DRB1\*01/15* and 85 *HLA-DRB1\*15/X* observed genotypes in the offspring. The number of *HLA-DRB1\*01/15* children was significantly decreased from the number of *HLA-DRB1\*15/X* offspring; OR = 0.59, χ^2^ = 9.1 (*p* = 0.0026, *p*~c~ = 0.036).

Case and Pseudo-Control Analysis {#s2i}
--------------------------------

*HLA-DRB1* alleles affecting MS risk were assessed by stepwise model selection, starting with a full model containing effects of each allele observed in the sample with frequency of at least ten across cases and pseudo-controls. Four alleles, *HLA-DRB1\*15*, *HLA-DRB1\*14*, *HLA-DRB1\*17,* and *HLA-DRB1\*11,* are significantly associated with disease. The same model was obtained using forward selection from the null model. The overall fit of the model was assessed by means of the Wald χ^2^ statistic of 258.58 on four degrees of freedom, providing strong evidence of association of *HLA-DRB1* alleles with MS (*p* = 9.2 × 10^−55^).

Model selection techniques tend to over fit the data, and result in increased false positive error rates for detecting association with disease. To overcome this problem, we performed 1,000 random permutations of case and pseudo-control status within each matched set. In none of the permutations did the selected model fit as well as in the original data, corresponding to an empirical *p*-value of less than 0.001 for association of *HLA-DRB1* alleles with MS.

[Table 6](#pgen-0030150-t006){ref-type="table"} presents the ORs of MS for each associated allele, relative to all non-associated alleles, denoted *HLA-DRB1\*X* forthwith. The strongest effect is observed for allele *HLA-DRB1\*15,* which increases risk of MS (OR = 2.46, *p* = 1.2 × 10^−47^). Allele *HLA-DRB1\*17* also increases risk of MS (OR = 1.28, *p* = 0.0021). Alleles *HLA-DRB1\*14* and *HLA-DRB1\*11* are protective against MS (ORs = 0.41 and 0.77, respectively; *p* = 4.9 × 10^−5^ and *p* = 0.0080, respectively).

###### 

Allelic ORs of MS for Associated Alleles at the HLA-DRB1 Locus, Relative to All Non-associated Alleles
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We next investigated deviations from a multiplicative model of disease risk between associated alleles. We generated a full model including a non-multiplicative effect for each associated allele, and interactions between each pair of associated alleles. Application of stepwise model selection, starting with the full model, dropped all interaction terms and non-multiplicative terms, apart from a dominance effect of the *HLA-DRB1\*15* allele (OR 0.68, *p* = 0.0078). Associated alleles act in a multiplicative fashion with respect to risk of MS, except for allele *HLA-DRB1\*15,* which acts in an additive fashion with itself.

[Table 7](#pgen-0030150-t007){ref-type="table"} presents ORs of MS for each *HLA-DRB1* genotype, relative to *HLA-DRB1\*X* homozygotes. As described above, the risk of associated alleles acts in a multiplicative fashion so that, e.g., an individual carrying one copy of the high-risk *HLA-DRB1\*15* allele and one copy of the strongly protective *HLA-DRB1\*14* allele has the same risk of MS as a *HLA-DRB1\*X/X* individual (OR = 1.06, *p* = 0.85). In other words, the effect of the *HLA-DRB1\*15* allele is cancelled out by the *HLA-DRB1\*14* allele. The *HLA-DRB1\*11* allele also provides some protection against the *HLA-DRB1\*15* allele, since the risk of the *HLA-DRB1\*11/15* genotype is lower than that of the *HLA-DRB1\*15/X* genotype (OR = 2.44 and 2.92, respectively). *HLA-DRB1\*11* provides protection against the high-risk *HLA-DRB1\*17* allele (OR of the *HLA-DRB1\*11/17* genotype = 0.98, *p* = 0.93). The *HLA-DRB1\*15* allele acts in a nonmultiplicative fashion with itself. Individuals homozygous for the *HLA-DRB1\*15* allele are at less risk of MS compared to the *HLA-DRB1\*15/X* genotype than would be expected under a multiplicative disease model (OR = 5.43 and 2.92, respectively).

###### 

Genotypic ORs of MS Made Up of Associated Alleles at the HLA-DRB1 Locus, Relative to HLA-DRB1\*X Homozygotes

![](pgen.0030150.t007)

Interaction of the *HLA-DRB1\*15* Allele with Non-associated Alleles {#s2j}
--------------------------------------------------------------------

Previous studies have shown that non-associated alleles at the *HLA-DRB1* locus interact with the *HLA-DRB1\*15* allele to modulate disease risk \[[@pgen-0030150-b010]\]. We investigated this by including interaction effects of each non-associated allele with *HLA-DRB1\*15* in a full association model. Stepwise model selection dropped all interaction terms, with the exception of the effects of the *HLA-DRB1\*07/15*, *HLA-DRB1\*08/15,* and *HLA-DRB1\*10/15* genotypes. The *HLA-DRB1\*07/15* and *HLA-DRB1\*08/15* genotypes demonstrate increased risk of MS compared to the *HLA-DRB1\*X/15* genotype (OR = 1.28 and 1.65, respectively; *p* = 0.038 and *p* = 0.016, respectively). On the other hand, the HLA*-DRB1\*10/15* appears protective compared to the *HLA-DRB1\*X/15* genotype (OR = 0.12, *p* = 0.044).

Discussion {#s3}
==========

The only consistent genetic association with MS in Northern Europeans has been with extended MHC haplotypes, especially those containing *HLA-DRB1\*1501* \[[@pgen-0030150-b008]\]. A previously linked region on Chromosome 5p13 \[[@pgen-0030150-b014]\] has been shown to harbor the interleukin 7 receptor gene *(IL7R),* an additional MS susceptibility locus \[[@pgen-0030150-b015]\], but any effect of *IL7R* is small (OR = 1.3), and when compared to the MHC (genotypic OR = 5.4, *p* = 5 × 10^−33^), its effect size is clearly too small to influence inheritance patterns. The MS MHC association has been used to add to circumstantial evidence supporting an autoimmune reaction against myelin-related antigens presented to T cells in the restricting context of *HLA-DRB1\*1501*. However, the specific susceptibility gene (e.g., *HLA-DR* or *HLA-DQ*) or the specific mechanism of class II determined susceptibility has yet to be convincingly elucidated. Recent scans of the MHC region with a large number of markers do show evidence for the involvement of *HLA-DRB1* only \[[@pgen-0030150-b016]\]. However, the paradigm is more complex than one in which the *HLA-DRB1\*15* allele acts solely to increase MS risk \[[@pgen-0030150-b010],[@pgen-0030150-b013]\]. Our previous investigation showed the presence of *HLA-DRB1\*14* as a resistance allele, *HLA-DRB1\*17* as a susceptibility allele, and the more compelling observation that alleles are interacting and that it is the genotype that determines MS risk \[[@pgen-0030150-b010]\]. This expanded Canadian dataset extends these results. We confirm that *HLA-DRB1\*15-* and *HLA-DRB1\*17*-bearing haplotypes increase risk of MS, and *HLA-DRB1\*14*-bearing haplotypes are protective, and show that *HLA-DRB1\*11*-bearing haplotypes are novel and statistically significant resistance haplotypes ([Table 6](#pgen-0030150-t006){ref-type="table"}). To our knowledge, this study provides the most comprehensive analysis to date of HLA susceptibility and resistance alleles for multiple sclerosis.

The protective effect of the *HLA-DRB1\*14* haplotype is shown to be multiplicative and completely abrogates the risk associated with *HLA-DRB1\*15* ([Table 7](#pgen-0030150-t007){ref-type="table"}). *HLA-DRB1\*14* homozygotes were not observed in our sample (either affected or unaffected relatives) in order to assess a possible increased protection conferred by *HLA-DRB1\*14* homozygosity, analogous to the increased susceptibility conferred by *HLA-DRB1\*15* and *DRB1\*17* homozygosity. In populations with a high frequency of *HLA-DRB1\*14*, e.g., China \[[@pgen-0030150-b017]\], where the existence of *HLA-DRB1\*14* homozygotes may be substantial, the prevalence of MS is extremely low. Thus, *HLA-DRB1\*14* could influence the distribution of MS and suggests more broadly that the *HLA-DRB1* genotype, which reflects more complex interactions, may be a major determinant of the heretofore unexplained geography of this disease.

*HLA-DRB1\*11* haplotypes also show a multiplicative mode of inheritance ([Table 7](#pgen-0030150-t007){ref-type="table"}). The protective effect of *HLA-DRB1\*11* over *HLA-DRB1\*15* appears to be weaker than that of *HLA-DRB1\*14,* but both reduce the risk associated with *HLA-DRB1\*17*.

We now show that *HLA-DRB1\*10-*bearing haplotypes are similar to *HLA-DRB1\*01-*bearing haplotypes in that they are both significantly under transmitted in the presence of *HLA-DRB1\*15*, showing a clear protective effect in the presence of *HLA-DRB1\*15* ([Table 5](#pgen-0030150-t005){ref-type="table"}). *HLA-DRB1\*10* and *HLA-DRB1\*01* were not under transmitted in the presence of *HLA-DRB1\*17* (unpublished data).

*HLA-DRB1\*15* heterozygotes have an increased risk of MS with an OR of 2.9 ([Tables 1](#pgen-0030150-t001){ref-type="table"} and [7](#pgen-0030150-t007){ref-type="table"}). The *HLA-DRB1\*15/15* offspring genotype also increases risk over *HLA-DRB1\*X/X* by 5.4-fold, and is in keeping with an additive mode of inheritance for *HLA-DRB1\*15,* similar to other studies \[[@pgen-0030150-b012],[@pgen-0030150-b018]--[@pgen-0030150-b021]\].

When the relative effects of *HLA-DRB1\*15* versus *HLA-DRB1\*17* were compared, *HLA-DRB1\*15* was found to be preferentially transmitted, most notably when transmissions from *HLA-DRB1\*17/15* heterozygous parents were counted, thereby ruling out a codominant model for these two risk alleles. This is also in keeping with previous observations \[[@pgen-0030150-b010]\].

Past studies have reported that *HLA-DRB1\*17* acts in a recessive manner \[[@pgen-0030150-b012],[@pgen-0030150-b013],[@pgen-0030150-b021]\]**,** but the sample size has been smaller than the one in the present study. In this Canadian sample, *HLA-DRB1\*17* haplotypes act in an additive fashion ([Tables 2](#pgen-0030150-t002){ref-type="table"} and [7](#pgen-0030150-t007){ref-type="table"}).

*HLA-DRB1\*08* increases risk significantly with *HLA-DRB1\*15* in *trans*. Thus, *HLA-DRB1\*08* shows a synergistic mode of inheritance with *HLA-DRB1\*15. HLA-DRB1\*17* shows no interaction with *HLA-DRB1\*08* (unpublished data), further highlighting the difference between *HLA-DRB1\*15* and *HLA-DRB1\*17* haplotypes.

As yet, no molecular or functional explanation can be given for the dominant-negative effects of *HLA-DRB1\*14* and *DRB1\*11,* the complementary effects of *HLA-DRB1\*08,* and the protective nature of *HLA-DRB1\*01* and *DRB1\*10* in the presence of *HLA-DRB1\*15*. It has been speculated that poor engagement of the encephalitogenic peptide in the context of *HLA-DRB1\*14* acts to alter the immune response in a dominant-negative manner and thereby reduce the effect of *HLA-DRB1\*15* \[[@pgen-0030150-b013]\]. Another explanation is that *HLA-DRB1\*14* binds one or more peptides that can delete autoreactive T cells. Alternatively, other risk factors present on *HLA-DRB1* haplotypes could be interacting in *cis* and *trans* to reduce MS risk. *HLA-DRB1* allelic association with MS susceptibility and resistance may reflect linkage disequilibrium with the true disease locus/loci. The identity and location of these putative variants are unknown and will be difficult to identify given the high linkage disequilibrium present within the MHC, although it is likely that these variants, if they exist, will be found in the class II region \[[@pgen-0030150-b016],[@pgen-0030150-b022]\]. Susceptibility and resistance haplotypes may need revisiting if/when true or additional MS MHC susceptibility loci are uncovered. As mentioned previously \[[@pgen-0030150-b010]\], *HLA-DRB1\*14, DRB1\*10,* and *DRB1\*01* share the extended *HLA-DQ* haplotype *HLA-DQA1\*01-DQB1\*05,* which may protect against MS*.* However*, HLA-DRB1\*11* haplotypes do not share these *HLA-DQ* alleles. Interestingly, phylogenetic analysis suggests that *HLA-DRB1\*10* and *DRB1\*01* share the same allelic lineage (DR1 group) and *HLA-DRB1\*11*, *DRB1\*14,* and *DRB1\*12* belong to the DR52 group \[[@pgen-0030150-b023]\]. Variants on the similar *HLA-DRB1\*10* and *DRB1\*01* haplotypes could enable them to be protective in the presence of *HLA-DRB1\*15*. *HLA-DRB1\*14* and *DRB1\*11* haplotypes may also possess similar polymorphisms that give them a dominant-protective effect.

It has been shown that low immune responsiveness to certain antigens are HLA-linked dominant traits \[[@pgen-0030150-b024]\]; this was proposed to be caused by an immune suppression gene present on certain HLA haplotypes that controls the generation of antigen-specific suppressor T cells \[[@pgen-0030150-b025]\]. Recently, *HLA-DRB5\*0101* has been shown to reduce the number of autoreactive CD4^+^ T cells in experimental autoimmune encephalomyelitis models \[[@pgen-0030150-b026]\]. It is conceivable that dominant variants on *HLA-DRB1\*14* and *HLA-DRB1\*11* haplotypes can generate T cells that suppress autoreactive T cells, even those generated by *HLA-DRB1\*15*.

This study highlights the need for a large sample size and systematic methods of analysis (e.g., stratified TDT is a more sensitive measure to detect interactions between alleles than regression) in order to unravel the complexity of HLA associations. Further studies of HLA expression, and/or animal models incorporating the susceptibility and resistance genotypes, are warranted to explain these complex interactions. In the meantime, genotyping for susceptibility and resistance alleles may have some practical value in prospective studies of prevention.

Materials and Methods {#s4}
=====================

Participants. {#s4a}
-------------

All participants in the study were ascertained through the ongoing CCPGSMS, for which the methodology has been previously described \[[@pgen-0030150-b027]\].

Genotyping. {#s4b}
-----------

Total genomic DNA, extracted from whole blood as part of the CCPGSMS, was used to type HLA-DRB1 alleles by an allele-specific PCR amplification method \[[@pgen-0030150-b028]\]. All genotypes were generated blind to pedigree structure and disease status of the individual. Either 24 (low resolution) or 72 (high resolution) PCRs were carried out to amplify allelotypes corresponding to alleles HLA-DRB1\*01, HLA-DRB1\*04, HLA-DRB1\*07, HLA-DRB1\*08, HLA-DRB1\*09, HLA-DRB1\*10, HLA-DRB1\*11, HLA-DRB1\*12, HLA-DRB1\*13, HLA-DRB1\*14, HLA-DRB1\*15, HLA-DRB1\*16, HLA-DRB1\*17, and HLA-DRB1\*18, as well as products for the DRB3, DRB4, and DRB5 genes. Each HLA-DRB1 genotype was scored twice by independent observers.

Statistical analyses. {#s4c}
---------------------

TDT was performed using the sib_tdt program of the ASPEX 2.3 analysis package (available at <http://aspex.sourceforge.net/>). The TDT counts the number of times an allele is transmitted to affected offspring from heterozygous parents. For TDTs the χ^2^ distribution was used to assess significance, except in TDTs where the sum of transmissions and non-transmissions was less than 50, when the exact binomial test was used. For allele inheritance analysis, a highly conservative Bonferroni correction was applied to correct for the number of statistical tests made for each allele, and for the total number of alleles investigated (*n* = 7). Corrected *p*-values are shown as *p*~c~.

Association of HLA-DRB1 alleles with MS was assessed by conditional logistic regression with each MS case matched to pseudo-controls, formed from the possible offspring that could have occurred from the parental mating \[[@pgen-0030150-b029]\]. The genotype of each individual was coded in terms of an indicator variable (0, 1, or 2) for each allele. Association of HLA-DRB1 alleles was then assessed by stepwise model selection, with allelic effects added or removed at each stage if *p* \< 0.05. Dominance effects of each allele were coded by additional indicator variables, taking the value 1 if an individual is homozygous for the allele and 0 otherwise. Interaction effects between alleles were generated by introducing further indicator variables that are products of the corresponding allelic effects. To allow for correlations between multiple affected offspring from the same family, cases and matched pseudo-controls were clustered by pedigree and robust Huber-White estimators used to adjust the standard errors of ORs \[[@pgen-0030150-b030]\].
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:   Canadian Collaborative Project on the Genetic Susceptibility to MS

HLA
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